A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate.
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2014
At a glance
- Drugs BMS 817399 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 17 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2013 Actual initiation date changed from Feb 2011 to Sep 2011 as reported by ClinicalTrials.gov.